Pneumotox. vs PLCOm2012 LCRC

Pneumotox®: The drug-induced/iatrogenic respiratory disease website & App. The companion website and App Cardiotox® cover drug-induced cardiotoxicity. By Philippe Camus MD. Professor (emeritus) - Board-certified in pulmonary medicine and cardiology,- Université Bourgone-Europe, Dijon, France. Pneumotox is an aid to the diagnosis and management of respiratory diseases and reactions suspected of being induced by drugs, chemicals, and of iatrogenic origin. Causality assessment and exact diagnosis are the full responsibility of the user. Pneumotox is designed to provide regularly-updated information on drugs causing pulmonary toxicity (>1,700 agents), patterns of involvement (>820) and bibliography (>10,700 as of August 2026) within a few minutes. That may be the crux in emergency situations. Yet, double-checking in and from other sources is indicated. Pneumotox rests on a bibliographic repository built since 1978, which amounts to >50,000 references overall, the vast majority of which is indexed in PubMed. All references were and are carefully reviewed for reliability and causality by the founder, then indexed under the corresponding drug or agent in Pneumotox. Pneumotox can be assessed by causative drug(s), chemicals, herbals, substances of abuse, inhaled incl. e-cigarettes, vaping, inhalants, gases, ionizing radiations (providing the list of patterns), or by patterns of involvement (providing the list of causal drugs/agents). Drug names are generic (International Nonproprietary Names (INN), alphabetical), not brand ones. It may be appropriate to check the exact composition of any proprietary drug, as any other added substance or excipient can be pneumotoxic. Matching generic and brand names which differs with country is the responsibility of the user. Patterns are grouped by families according to the main anatomic site of involvement. If a drug or drug reaction is listed in Pneumotox, that does not equate the patient is demonstrating toxicity. A “Diagnosing DIRD” window in Pneumotox (top panel) may help secure the diagnosis. Lack of case or cases in the literature or in Pneumotox does not exclude a diagnosis of drug toxicity as there may be unpublished cases, you may be seeing the first case ever, or we may have overlooked some information. In such situations, please inform us; Pneumotox cannot be held responsible. Pneumotox can be contacted by mail 7/365 for complementary information, tailored literature, and/or data on rechallenge with the drug. In any patient, particularly the ones with acute respiratory failure, ARDS or acute bronchospasm, exposure to drugs, substances, and/or chemicals must be done exhaustively with the patient, and if needed with the family, health professionals, pharmacy and/or law enforcement personel. And prompt removal of the drug can be lifesaving. Caution: drug withdrawal can produce a flare of the underlying condition for which the drug was exactly given. Deliberate rechallenge can be hazardous as fatal relapse of the respiratiory reaction can supervene. Early sampling of body fluids for drug and/or metabolites is indicated as early as possible, particularly in the severely ill. Knowledge of toxidromes and antidotes capable of countering adverse effects of drugs or chemicals is essential (ex: PMID ). Where in doubt, consider double-checking PubMed, your affiliated Safety for Medicines Department/Agency and the Pharmacovigilance Department of drug companies. They may host more and/or undisclosed information. Patients should be reassured as such incidents are rare oveall. If needed, they are invited to consult with their treating physicians. Monitoring common causal agents (with red digits in stars) for impending toxicity is strongly advised. You may contact Pneumotox anytime through the contact window. ALL RIGHTS RESERVED The current version of Pneumotox website and App were developed by Akyos Communication Dijon France, under the guidance of Philippe Camus MD

This app is for use by people who currently smoke or used to smoke. It is a lung cancer risk calculator. It calculates your six-year risk of developing lung cancer based on your age, formal education, height and weight, family history of lung cancer, your cancer and lung health history, and your smoking history. There are two versions of the app. The only difference is one version, PLCOm2012 includes race as an input and the other version, PLCOm2012noRace does not have race as an input. The PLCOm2012noRace version is appropriate for use outside of the United States. You can take the risk calculated by this app to your health care professional and discuss if you should be screened for lung cancer and to see if you are eligible for screening in your area. This app can also be used by health care professionals with their patients to assess risk of lung cancer in a shared decision-making discussion about the benefits and potential risks of screening. The calculator is based on the PLCOm2012 lung cancer risk prediction model developed by Professor Martin Tammemägi. It has been validated by many researchers in multiple countries and is used in lung cancer screening studies, pilots and programs around the world. The PLCOm2012 app version has been simplified by reducing race/ethnic categories from 7 to 3. The PLCOm2012noRace app has been simplified by taking race out as an input. Performance of the modified models are almost identical to the initial model and in some measures are improved. Any information you enter into this application will only be stored on your device while you are using the risk calculator. All input fields will be reset after you exit the app. The PLCOm2012 and PLCOm2012noRace LCRC apps work off-line and do not use internet connections. Your personal information is not collected or stored anywhere outside of your smartphone, so it is not possible for your information to be shared with others. The PLCOm2012 and PLCOm2012noRace LCRC apps were developed as a public service by epidemiologist Martin Tammemägi DVM, MSc, PhD and patient advocate Andrea Borondy Kitts MS, MPH. They are provided free of charge and free of advertising to the general public and the medical community. Disclaimer The content of the PLCOm2012 and PLCOm2012noRace LCRC apps are based on scientific research. But information provided here should not be substituted for a physician’s evaluation, advice, diagnosis or treatment. Your doctor is the most appropriate person to provide you with guidance on specific health issues. If you are currently ill or have symptoms, seek the help of your health care provider. If you currently smoke, one of the most important health decisions you can make, is to quit smoking. Your doctor should be able to help you quit more successfully. No cancer prediction model is 100% accurate. It is important to appreciate that some individuals with low predicted risks will develop lung cancer, and not all individuals with high risk scores will develop lung cancer. We provide the PLCOm2012 and PLCOm2012noRace Lung Cancer Risk Calculators apps (PLCOm2012 and PLCOm2012noRace LCRC apps) as a public service only and you use them at your own risk.